The selected cohort represents a diverse approach to heart health. Chicago-based Flow Medical is refining catheter-directed thrombolysis for pulmonary embolisms, while Norway’s Mode Sensors introduces non-invasive fluid monitoring via its ReBalans system. From Europe, Berlin’s Noah Labs uses AI-driven voice analysis to predict cardiac decompensation, Galway’s Galenband offers a 90-day wearable telemetry patch, and France-based Omini provides a portable platform for rapid blood biomarker testing.
In section Releases
HeartX Names Five Cardiovascular Startups for 2026 Accelerator
Five global healthcare startups have secured spots in the 2026 HeartX accelerator program, each receiving a $150,000 investment and a guaranteed clinical pilot. The initiative, run by HealthTech Arkansas and MedAxiom, aims to bridge the gap between emerging medical technology and real-world cardiovascular care environments.
Jeff Stinson, director of HTA, noted that the program’s value lies in moving these innovations directly into clinical settings alongside providers. This hands-on collaboration is designed to validate technologies that address persistent gaps in treatment, from early detection to personalized care. The cohort will officially launch its work at the CV Transforum conference in Denver, scheduled for October 22–24.
Comments (0)
No comments yet. Be the first!